Stryker Corporation $SYK Position Increased by Consolidated Investment Group LLC

Consolidated Investment Group LLC increased its stake in Stryker Corporation (NYSE:SYK) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,110 shares of the medical technology company’s stock after purchasing an additional 2,600 shares during the period. Consolidated Investment Group LLC’s holdings in Stryker were worth $4,608,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in SYK. Clayton Financial Group LLC bought a new stake in shares of Stryker in the 3rd quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the 3rd quarter valued at $27,000. Strive Asset Management LLC bought a new stake in Stryker during the 3rd quarter valued at $30,000. ANTIPODES PARTNERS Ltd bought a new stake in Stryker during the 3rd quarter valued at $34,000. Finally, Copia Wealth Management raised its stake in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after acquiring an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 1.2%

Shares of SYK stock opened at $341.74 on Thursday. Stryker Corporation has a 1 year low of $319.32 and a 1 year high of $404.87. The stock has a market cap of $130.88 billion, a PE ratio of 40.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.92. The business’s fifty day moving average is $353.78 and its 200-day moving average is $359.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period last year, the firm earned $4.01 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent analyst reports. Sanford C. Bernstein lifted their target price on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Citigroup cut their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Truist Financial cut their target price on Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a research note on Wednesday. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, The Goldman Sachs Group cut their target price on Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $421.11.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker agreed to acquire Amplitude Vascular Systems to add next‑generation IVL technology, expanding its peripheral vascular offerings and potentially accelerating addressable market growth in arterial disease — a strategic tuck‑in that investors generally view as growth‑accretive. Stryker to Acquire AVS (Zacks)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $397 price target, signaling continued analyst confidence in Stryker’s growth and supporting upside expectations for the stock. BTIG Buy Reaffirmed
• Positive Sentiment: Leerink Partners initiated coverage on Stryker with an outperform/recommendation, adding another supportive institutional view that may help underpin the stock over time. Leerink Initiates Coverage (MSN)
• Neutral Sentiment: A separate initiation notice was posted by AmericanBankingNews; initiation increases institutional coverage and liquidity but its immediate directional impact depends on the report’s stance and investor reaction. Leerink Initiates Coverage (AmericanBankingNews)
• Negative Sentiment: Truist lowered its price target from $395 to $380 and moved to a “hold” rating, reducing the implied upside and contributing to near‑term selling pressure as some investors mark positions to the lower PT. Truist Lowers Price Target (Benzinga)

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.